3rd International AIDS Society Conference on HIV Pathogenesis and Treatment Rio de Janeiro - July 24 - 27, 2005

THE FOTO STUDY 48 WEEK RESULTS: VIRAL SUPPRESSION CAN BE MAINTAINED WHEN ANTIRETROVIRALS ARE TAKEN FIVE CONSECUTIVE DAYS ON, AND TWO DAYS OFF EACH WEEK

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. WePe12.4C10

Cohen C.¹, Colson A.¹, Morris A.¹, Alberts L.², Sheble-Hall A.¹, Hussey S.¹, Schulte M.^3
1CRI New England, Boston, United States of America, ²CRI Provincetown, Provincetown, United States of America, ³CRI Springfield, Springfield, United States of America

INTRODUCTION: We evaluated viral load (VL), CD4s, and QOL when changing from daily antiretroviral therapy (ART) to a weekly schedule of 5-days-on treatment and 2-days-off treatment (5/2). This schedule was chosen to enhance adherence by mimicking the work week and to minimize risk of VL rebound by keeping interruptions brief.

METHODS: N=30 HIV+ adults with VL<50 and CD4s >200 on stable ART for >3 months. At enrollment, subjects changed from daily ART to 5/2. Subjects with VL rebound (>500 × 2) resumed daily ART. Change in CD4 and lipids was analyzed using repeated measure ANOVA.

RESULTS:

Three on NNRTIs and one on PIs were LTFU before wk 48. Two on PIs had confirmed VL rebound, one on NVP had unconfirmed rebound; all resuppressed on daily ART. Mean LDL Chol fell from 116 at baseline to 103 at week 48(p=0.016); this was driven by changes in the PI arm. There were no significant changes to HDL or TG. No significant changes were seen to CD4 counts. Twenty of 23 completing week 24 completed a Likert scale: 0 was strong preference for daily Rx, 10 was strong preference for 5/2. The mean score was 9.8.

CONCLUSIONS: In this pilot, ART 5 consecutive days per week maintains virologic suppression for at least 48 weeks in 100% on EFV/NRTI regimens; lower rates were seen with PIs. The 5/2 schedule is strongly preferred by subjects, and reduces ART costs by 28%. If results are confirmed, these results have enormous implications especially for developing nations.

Download PDF of this abstract.

050724
Clinical | WePe12.4C10 | Calvin Cohen
Treatment Interruption

Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.